Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-11-17

Clinical Trial Update: Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase II study of bexarotene in Acute Myeloid Leukemia was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bexarotene (Bexarotene)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2020-11-17